These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 34233960)

  • 21. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
    Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing.
    Appelbaum J; Price AE; Oda K; Zhang J; Leung WH; Tampella G; Xia D; So PP; Hilton SK; Evandy C; Sarkar S; Martin U; Krostag AR; Leonardi M; Zak DE; Logan R; Lewis P; Franke-Welch S; Ngwenyama N; Fitzgerald M; Tulberg N; Rawlings-Rhea S; Gardner RA; Jones K; Sanabria A; Crago W; Timmer J; Hollands A; Eckelman B; Bilic S; Woodworth J; Lamble A; Gregory PD; Jarjour J; Pogson M; Gustafson JA; Astrakhan A; Jensen MC
    J Clin Invest; 2024 Mar; 134(9):. PubMed ID: 38502193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia.
    Gomes-Silva D; Atilla E; Atilla PA; Mo F; Tashiro H; Srinivasan M; Lulla P; Rouce RH; Cabral JMS; Ramos CA; Brenner MK; Mamonkin M
    Mol Ther; 2019 Jan; 27(1):272-280. PubMed ID: 30391141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.
    Calviño C; Ceballos C; Alfonso A; Jauregui P; Calleja-Cervantes ME; San Martin-Uriz P; Rodriguez-Marquez P; Martin-Mallo A; Iglesias E; Abizanda G; Rodriguez-Diaz S; Martinez-Turrillas R; Illarramendi J; Viguria MC; Redondo M; Rifon J; Villar S; Lasarte JJ; Inoges S; Lopez-Diaz de Cerio A; Hernaez M; Prosper F; Rodriguez-Madoz JR
    Front Immunol; 2023; 14():1270843. PubMed ID: 37795087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System.
    Rotiroti MC; Buracchi C; Arcangeli S; Galimberti S; Valsecchi MG; Perriello VM; Rasko T; Alberti G; Magnani CF; Cappuzzello C; Lundberg F; Pande A; Dastoli G; Introna M; Serafini M; Biagi E; Izsvák Z; Biondi A; Tettamanti S
    Mol Ther; 2020 Sep; 28(9):1974-1986. PubMed ID: 32526203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Engineering tandem CD33xCD146 CAR CIK (cytokine-induced killer) cells to target the acute myeloid leukemia niche.
    Alberti G; Arsuffi C; Pievani A; Salerno D; Mantegazza F; Dazzi F; Biondi A; Tettamanti S; Serafini M
    Front Immunol; 2023; 14():1192333. PubMed ID: 37304257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells.
    Mueller J; Schimmer RR; Koch C; Schneiter F; Fullin J; Lysenko V; Pellegrino C; Klemm N; Russkamp N; Myburgh R; Volta L; Theocharides AP; Kurppa KJ; Ebert BL; Schroeder T; Manz MG; Boettcher S
    EMBO Mol Med; 2024 Mar; 16(3):445-474. PubMed ID: 38355749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia.
    Le Q; Castro S; Tang T; Loeb AM; Hylkema T; McKay CN; Perkins L; Srivastava S; Call L; Smith J; Leonti A; Ries R; Pardo L; Loken MR; Correnti C; Fiorenza S; Turtle CJ; Riddell S; Tarlock K; Meshinchi S
    Clin Cancer Res; 2021 Oct; 27(20):5718-5730. PubMed ID: 34380639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells.
    Lee WS; Ye Z; Cheung AMS; Goh YPS; Oh HLJ; Rajarethinam R; Yeo SP; Soh MK; Chan EHL; Tan LK; Tan SY; Chuah C; Chng WJ; Connolly JE; Wang CI
    Mol Cancer Ther; 2021 Sep; 20(9):1702-1712. PubMed ID: 34158344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A CD123-specific chimeric antigen receptor augments anti-acute myeloid leukemia activity of Vγ9Vδ2 T cells.
    Zhang X; Ang WX; Du Z; Ng YY; Zha S; Chen C; Xiao L; Ng JY; Chng WJ; Wang S
    Immunotherapy; 2022 Apr; 14(5):321-336. PubMed ID: 35152722
    [No Abstract]   [Full Text] [Related]  

  • 31. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
    Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ
    Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generation of Suicide Gene-Modified Chimeric Antigen Receptor-Redirected T-Cells for Cancer Immunotherapy.
    Minagawa K; Al-Obaidi M; Di Stasi A
    Methods Mol Biol; 2019; 1895():57-73. PubMed ID: 30539529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-Acute Myeloid Leukemia Activity of CD38-CAR-T Cells with PI3Kδ Downregulation.
    An N; Pan Y; Yang L; Zhang Q; Deng S; Zhang Q; Du X
    Mol Pharm; 2023 May; 20(5):2426-2435. PubMed ID: 37021820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How close are we to CAR T-cell therapy for AML?
    Gill SI
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101104. PubMed ID: 31779970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The tandem CD33-CLL1 CAR-T as an approach to treat acute myeloid leukemia.
    Wang H; Feng S; Zhu Y; Zhang Y; Zhou Z; Nian Z; Lu X; Peng P; Wu S; Zhou L
    Blood Transfus; 2024 Aug; ():. PubMed ID: 39133622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cooperative CAR targeting to selectively eliminate AML and minimize escape.
    Haubner S; Mansilla-Soto J; Nataraj S; Kogel F; Chang Q; de Stanchina E; Lopez M; Ng MR; Fraser K; Subklewe M; Park JH; Wang X; Rivière I; Sadelain M
    Cancer Cell; 2023 Nov; 41(11):1871-1891.e6. PubMed ID: 37802054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CAR T-cells targeting FLT3 have potent activity against FLT3
    Jetani H; Garcia-Cadenas I; Nerreter T; Thomas S; Rydzek J; Meijide JB; Bonig H; Herr W; Sierra J; Einsele H; Hudecek M
    Leukemia; 2018 May; 32(5):1168-1179. PubMed ID: 29472720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity.
    Richards RM; Zhao F; Freitas KA; Parker KR; Xu P; Fan A; Sotillo E; Daugaard M; Oo HZ; Liu J; Hong WJ; Sorensen PH; Chang HY; Satpathy AT; Majzner RG; Majeti R; Mackall CL
    Blood Cancer Discov; 2021 Nov; 2(6):648-665. PubMed ID: 34778803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Current status and future perspective of CAR T-cell therapy for acute myeloid leukemia].
    Nakazawa Y
    Rinsho Ketsueki; 2022; 63(10):1446-1453. PubMed ID: 36351654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia.
    Albinger N; Pfeifer R; Nitsche M; Mertlitz S; Campe J; Stein K; Kreyenberg H; Schubert R; Quadflieg M; Schneider D; Kühn MWM; Penack O; Zhang C; Möker N; Ullrich E
    Blood Cancer J; 2022 Apr; 12(4):61. PubMed ID: 35418180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.